Viking Therapeutics, Inc.

Viking Therapeutics, Inc.verified

VKTX

Price:

$50.9

Market Cap:

$5.61B

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug...[Read more]

Industry

Biotechnology

IPO Date

2015-04-28

Stock Exchange

NASDAQ

Ticker

VKTX

The Current Ratio as of June 2024 (TTM) for Viking Therapeutics, Inc. (VKTX) is 29.48

According to Viking Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 29.48. This represents a change of 10.48% compared to the average of 26.69 of the last 4 quarters.

Viking Therapeutics, Inc. (VKTX) Historical Current Ratio (quarterly & annually)

How has VKTX Current Ratio performed in the past?

The mean historical Current Ratio of Viking Therapeutics, Inc. over the last ten years is 19.25. The current 29.48 Current Ratio has changed 15.21% with respect to the historical average. Over the past ten years (40 quarters), VKTX's Current Ratio was at its highest in in the December 2018 quarter at 66.40. The Current Ratio was at its lowest in in the September 2014 quarter at 0.

Quarterly (TTM)
Annual

Average

19.25

Median

13.44

Minimum

0.03

Maximum

66.40

Viking Therapeutics, Inc. (VKTX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Viking Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 22.28%

Maximum Annual Current Ratio = 66.40

Minimum Annual Increase = -97.56%

Minimum Annual Current Ratio = 0.03

Quarterly (TTM)
Annual
YearCurrent RatioChange
202319.19152.15%
20227.61-68.27%
202123.9813.59%
202021.12-49.53%
201941.83-37.00%
201866.402.53%
20172.5216.99%
20162.16-71.94%
20157.6922.28%
20140.03-97.56%

Viking Therapeutics, Inc. (VKTX) Average Current Ratio

How has VKTX Current Ratio performed in the past?

The current Current Ratio of Viking Therapeutics, Inc. (VKTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

16.93

5-year avg

22.75

10-year avg

19.25

Viking Therapeutics, Inc. (VKTX) Current Ratio vs. Peers

How is VKTX’s Current Ratio compared to its peers?

Viking Therapeutics, Inc.’s Current Ratio is greater than Intercept Pharmaceuticals, Inc. (4.22), greater than Terns Pharmaceuticals, Inc. (27.85), less than Akero Therapeutics, Inc. (30.12), greater than Reata Pharmaceuticals, Inc. (3.21), greater than Madrigal Pharmaceuticals, Inc. (9.39), greater than Sarepta Therapeutics, Inc. (4.05), greater than Hepion Pharmaceuticals, Inc. (5.99), greater than PTC Therapeutics, Inc. (2.03), greater than Axsome Therapeutics, Inc. (3.20), greater than ImmunoGen, Inc. (5.47), greater than Seres Therapeutics, Inc. (1.68), greater than Day One Biopharmaceuticals, Inc. (10.93), greater than X4 Pharmaceuticals, Inc. (3.71), greater than Inozyme Pharma, Inc. (14.05), less than Acumen Pharmaceuticals, Inc. (30.20), greater than Mereo BioPharma Group plc (4.86), greater than AVROBIO, Inc. (26.17), greater than CohBar, Inc. (4.16), greater than Ocean Biomedical, Inc. (0.03), greater than Enveric Biosciences, Inc. (3.48), less than Elevation Oncology, Inc. (46.22),

Build a custom stock screener for Viking Therapeutics, Inc. (VKTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Viking Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Viking Therapeutics, Inc. (VKTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Viking Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Current Ratio?

How can you use the Current Ratio?

What is Viking Therapeutics, Inc.'s Current Ratio?

How is the Current Ratio calculated for Viking Therapeutics, Inc. (VKTX)?

What is the highest Current Ratio for Viking Therapeutics, Inc. (VKTX)?

What is the 3-year average Current Ratio for Viking Therapeutics, Inc. (VKTX)?

What is the 5-year average Current Ratio for Viking Therapeutics, Inc. (VKTX)?

How does the current Current Ratio for Viking Therapeutics, Inc. (VKTX) compare to its historical average?